Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas.

Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas.
复制标题

DOI:
10.18632/oncotarget.2390
复制
发表时间:
2014-10-30
期刊:
影响因子:
--
通讯作者:
Chim CS
Chim CS
中科院分区:
其他
文献类型:
--
作者:
Yim RL;Wong KY;Kwong YL;Loong F;Leung CY;Chu R;Lam WW;Hui PK;Lai R;Chim CS

文献摘要

参考文献

被引文献

相似文献

套细胞淋巴瘤(MCL)是一种侵袭性B细胞非霍奇金淋巴瘤(NHL)。在癌症中,肿瘤抑制性microRNA可以通过DNA超甲基化而沉默。通过对去甲基化处理前后的代表性EBV阴性MCL细胞系的microRNA分析,发现miR-155- 3 p显著恢复。通过焦磷酸测序验证的甲基化特异性PCR显示在一个MCL细胞系(REC-1)中miR-155- 3 p完全甲基化。5-aza-2′-deoxycytidine处理REC-1可导致miR-155- 3 p的去甲基化和重新表达。miR-155- 3 p的过表达导致亚G1期凋亡细胞增加和细胞活力降低,表明其肿瘤抑制特性。通过荧光素酶测定,验证了光敏素-β(LT-β)是miR-155- 3 p的靶标。在31例原发性MCL中,6例(19%)发现miR-155- 3 p高甲基化。为了测试miR-155- 3 p的甲基化是否是MCL特异性的,在另外191个B细胞、T细胞和NK细胞NHL中测试miR-155 - 3 p甲基化,在66个(34.6%)中产生miR-155 - 3 p甲基化,包括36个(27%)非MCL B细胞、24个(53%)T细胞和6个(46%)NK细胞淋巴瘤。此外,在72例有RNA的原发性NHL样本中,miR-155- 3 p甲基化与miR-155- 3 p下调(p = 0.024)和LT-β上调(p = 0.043)相关。总体而言,miR-155- 3 p是MCL和其他NHL亚型中高甲基化的潜在肿瘤抑制性microRNA。由于miR-155- 3 p靶向LT-β,LT-β是非经典NF-kB信号传导的上游激活剂,因此miR-155- 3 p甲基化在淋巴瘤发生中可能很重要。
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma (NHL). In cancers, tumor suppressive microRNAs may be silenced by DNA hypermethylation. By microRNA profiling of representative EBV-negative MCL cell lines before and after demethylation treatment, miR-155-3p was found significantly restored. Methylation-specific PCR, verified by pyrosequencing, showed complete methylation of miR-155-3p in one MCL cell line (REC-1). 5-aza-2′-deoxycytidine treatment of REC-1 led to demethylation and re-expression of miR-155-3p. Over-expression of miR-155-3p led to increased sub-G1 apoptotic cells and reduced cellular viability, demonstrating its tumor suppressive properties. By luciferase assay, lymphotoxin-beta (LT-β) was validated as a miR-155-3p target. In 31 primary MCL, miR-155-3p was found hypermethylated in 6(19%) cases. To test if methylation of miR-155-3p was MCL-specific, miR-155-3p methylation was tested in an additional 191 B-cell, T-cell and NK-cell NHLs, yielding miR-155-3p methylation in 66(34.6%) including 36(27%) non-MCL B-cell, 24(53%) T-cell and 6(46%) of NK-cell lymphoma. Moreover, in 72 primary NHL samples with RNA, miR-155-3p methylation correlated with miR-155-3p downregulation (p = 0.024), and LT-β upregulation (p = 0.043). Collectively, miR-155-3p is a potential tumor suppressive microRNA hypermethylated in MCL and other NHL subtypes. As miR-155-3p targets LT-β, which is an upstream activator of the non-canonical NF-kB signaling, miR-155-3p methylation is potentially important in lymphomagenesis.
血液恶性肿瘤中 hsa-miR-203 的表观遗传失活。
DOI: 10.1111/j.1582-4934.2011.01274.x
发表时间: 2011-12
影响因子: 5.3
作者:
Chim CS;Wong KY;Leung CY;Chung LP;Hui PK;Chan SY;Yu L
通讯作者: Yu L
DOI: 10.1038/nature08782
发表时间: 2010-03-11
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1182/blood.v91.8.2977.2977_2977_2984
发表时间: 1998-04-15
期刊: BLOOD
影响因子: 20.3
作者:
Pinyol, M;Cobo, F;Campo, E
通讯作者: Campo, E
DOI: 10.1158/1078-0432.ccr-11-0494
发表时间: 2011-07-15
影响因子: 11.5
作者:
Paik, Jin Ho;Jang, Ji-Young;Kim, Chul-Woo
通讯作者: Kim, Chul-Woo
DOI: 10.1182/blood-2010-09-301994
发表时间: 2011-06-16
期刊: BLOOD
影响因子: 20.3
作者:
Desjobert, Cecile;Renalier, Marie-Helene;Lamant, Laurence
通讯作者: Lamant, Laurence